|Day Low/High||45.78 / 47.06|
|52 Wk Low/High||42.48 / 63.69|
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
- Facility will support gene therapy production and continued development of pipeline of investigational medicines -
These stocks and sectors are safe havens, and may even be opportunities.
The most recent short interest data was recently released for the 04/15/2019 settlement date, and Bristol-Myers Squibb Co. is the #186 most shorted of the S&P 500 components, based on 4.20 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.
Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.
Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb's pending acquisition of Celgene Corporation (NASDAQ:CELG).
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti (elotuzumab) plus...
The non-consumer economy is just plain worrisome, says Jim Cramer, and our industrials are warning of weakness related to the trade war with China.
Stocks finish down Thursday, one day after the Nasdaq and the S&P 500 closed at record highs, as investors retreat from disappointing earnings reports.
Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.
Bristol-Myers Squibb posts stronger-than-expected second-quarter earnings and boost its full-year profit forecast while adding that its $74 billion acquisition of Celgene would likely close in early 2020.
And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2019, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab) and a robust operating performance across the portfolio.
U.S. stock futures are mixed on Thursday, a day after the S&P 500 and Nasdaq reached all-time highs, and ahead of the busiest day so far of the quarterly earnings season; Tesla falls sharply after posting a wider-than-expected loss and announcing its chief technology officer would be stepping down; Facebook's earnings top forecasts as monthly-active users rise; Amazon and Alphabet report earnings Thursday.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 2 of the Phase 3 CheckMate -227 trial did not meet the primary endpoint of overall survival (OS) with Opdivo ® (nivolumab) plus chemotherapy versus chemotherapy in patients with first-line...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo ® (nivolumab) plus low-dose Yervoy ® (ipilimumab) met the co-primary endpoint of overall survival (OS), demonstrating a superior...
Jim Cramer says we're heading into the busiest week of earnings season. He's got your game plan, but says it might be a good time to take your summer vacation.
- Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd.
Breaking down the impact on Facebook, Alphabet and Amazon of congressional hearings.
Jim Cramer says don't trade earnings season, invest in it -- and invest the time needed to be a smart, successful investor.
Jim Cramer weighs in on Bristol-Myers Squibb, Eli Lily, DuPont, Marvell Technology, General Motors, Kraft Heinz, Maxar Technologies, and more.
Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.